Unknown PHASE3 INTERVENTIONAL 2-arm NCT03236610

Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir

Investigation of Efficacy of Tenofovir Monotherapy in Comparison With Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir Combination Therapy-Multicenter Randomized Open-label Controlled Trial

Sponsor: Uijeongbu St. Mary Hospital

Conditions Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48

Interventions tenofovir monotherapy tenofovir plus entecavir combination

Updated 6 times since 2017 Last updated: Jul 28, 2017 Started: Jan 1, 2016 Primary completion: Jun 30, 2018 Completion: Jun 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48 and is currently ongoing. Uijeongbu St. Mary Hospital leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Aug 2019 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Sep 2017 — Aug 2019 [monthly]

Recruiting PHASE3

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Uijeongbu St. Mary Hospital

Data source: Uijeongbu St. Mary Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Uijongbu, South Korea